EligibleTrials

Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma

Recruiting · NCT04594187 · Interventional (participants receive a specific treatment) · Lead sponsor: M.D. Anderson Cancer Center

View the official record on ClinicalTrials.gov →
Melanoma

Interventions studied

ImmunotherapyQuality-of-Life AssessmentRadiation Therapy

What this trial is about

This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without completion lymph node dissection. Prior studies of patients with more advanced melanoma have shown nodal radiation therapy can decrease the risk of nodal recurrence but it is not known if this same benefit will be seen in patients with high risk sentinel lymph node positive disease who are planned for immunotherapy.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

3 locations listed across 3 US states.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.